Lonafarnib

Contraindicated

Lonafarnib Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of fatal toxicity Details Lonafarnib Simvastatin Flolipid Explained Increased simvastatin exposure and an increased risk of myopathy or rhabdomyolysis Details Lonafarnib Atorvastatin Atorvaliq Increased atorvastatin exposure and an increased risk of myopathy or rhabdomyolysis Details Lonafarnib Dihydroergotamine Injection DHE-45® Injection Increased dihydroergotamine exposure and an increased risk of dihydroergotamine-related adverse effects Details Lonafarnib Dihydroergotamine Nasal Spray Migranal Increased dihydroergotamine exposure and an increased risk of dihydroergotamine-related adverse effects Details Lonafarnib Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Lonafarnib Ivabradine Corlanor Increased ivabradine exposure, an increased risk of ivabradine-related adverse effects and an increased risk of QT prolongation Details Lonafarnib Ketoconazole Topical Extina® Foam Increased lonafarnib exposure, an increased risk of lonafarnib-related adverse effects and an increased risk of QT interval prolon... Details Lonafarnib Lovastatin Altocor® Increased lovastatin exposure and an increased risk of myopathy or rhabdomyolysis Details Lonafarnib Lurasidone Latuda Increased lurasidone exposure Details Lonafarnib Midazolam Nasal Spray Nayzilam Increased midazolam exposure and an increased risk of midazolam-related adverse effects Details Lonafarnib Midazolam Injection Nayzilam Increased midazolam exposure and an increased risk of midazolam-related adverse effects Details Lonafarnib Nafcillin Injection Unipen® Injection Reduced lonafarnib exposure and reduced efficacy of lonafarnib Details Lonafarnib Naloxegol Movantik Increased naloxegol exposure and an increased risk of naloxegol-related adverse effects Details

Major

Lonafarnib Acetaminophen And Codeine Capital® & Codeine Explained Increased codeine and morphine exposure Details Lonafarnib Clindamycin ANTIROBE Explained Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A substrate with NTI-related serious or life-threatening... Details Lonafarnib Omeprazole Gastrobim Explained Increased CYP2C19 substrate exposure and an increased risk of CYP2C19 substrate-related adverse effects Details Lonafarnib Amitriptyline Elavil Explained An increased risk of QT interval prolongation and torsade de pointes Details Lonafarnib Sertraline Explained An increased risk of QT interval prolongation and torsade de pointes Details Lonafarnib Buprenorphine Belbuca Explained Increased buprenorphine exposure, an increased risk of buprenorphine-related adverse events and an increased risk of QT interval p... Details Lonafarnib Relugolix Orgovyx Explained Increased relugolix exposure Details Lonafarnib Abemaciclib Verzenio Explained Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Lonafarnib Abrocitinib Cibinqo Explained Increased CYP2C19 substrate exposure and an increased risk of CYP2C19 substrate-related adverse effects Details Lonafarnib Acalabrutinib Calquence Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Lonafarnib Amisulpride Injection Barhemsys An increased risk of QT interval prolongation and torsade de pointes Details Lonafarnib Apixaban Eliquis Explained Increased apixaban exposure and an increased risk of bleeding Details Lonafarnib Arsenic Trioxide Trisenox An increased risk of QT interval prolongation and torsade de pointes Details Lonafarnib Aripiprazole Injection Abilify Increased ARIPiprazole exposure and an increased risk of QT interval prolongation and torsade de pointes Details Lonafarnib Arsenic Trioxide Injection Trisenox An increased risk of QT interval prolongation and torsade de pointes Details Lonafarnib Asciminib Scemblix Increased asciminib exposure and an increased risk of asciminib-related adverse effects Details Lonafarnib Asenapine Transdermal Patch Secuado An increased risk of QT interval prolongation and torsade de pointes Details Lonafarnib Atogepant Qulipta Increased atogepant exposure Details Lonafarnib Avapritinib Ayvakit Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Lonafarnib Azithromycin AzaSite An increased risk of QT interval prolongation and torsade de pointes Details Lonafarnib Cariprazine Vraylar Explained Increased exposure to cariprazine and its active metabolite, didesmethylcariprazine Details Lonafarnib Alfuzosin UroXatral An increased risk of QT interval prolongation and torsade de pointes Details Lonafarnib Amlodipine Amvaz® Increased amLODIPine exposure and an increased risk of hypotension and edema Details Lonafarnib Anagrelide Agrylin An increased risk of QT interval prolongation and torsade de pointes Details Lonafarnib Avanafil Stendra Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Lonafarnib Axitinib Inlyta Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A substrate with NTI-related serious or life-threatening... Details